Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome "Tor Vergata", Via Columbia 2, 00133, Rome, RM, Italy.
Institute for Leadership and Management in Health, Kingston University London, London, UK.
Clin Drug Investig. 2020 May;40(5):449-458. doi: 10.1007/s40261-020-00904-8.
Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs.
A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were calculated considering the administrative database of the hospital discharge records for the period 2008-2016. Patients were enrolled in the analysis if they report the subsequent inclusion criteria: age ≥ 45 years and presence of osteoporosis in primary or secondary diagnosis (ICD9-CM 733.0) and/or presence of a major fracture in primary or secondary diagnosis (excluding road accidents) in the following locations: spine (codes ICD9-CM: 805;806), femur (codes ICD9-CM: 820; 821), radius and ulna (codes ICD9-CM: 813.4; 813.5), humerus (codes ICD9-CM: 812.0-812.5), pelvis (code ICD9-CM: 808), tibia and fibula (codes ICD9-CM: 823), ankle (code ICD9: 824) and ribs (codes ICD9-CM: 807.0; 807.1). Costs were estimated considering the diagnosis-related group (DRG) national tariff associated with each hospitalisation. Finally, the administrative databases of the Italian National Social Security Institute (INPS) (2009-2015) were analysed for the estimate the pension and disability costs from the social perspective.
The model estimated an average annual economic burden of osteoporosis in Italy of €2.2 billion. Of this cost, approximately 80% (€1.8 billion) was associated with hospitalisations, 16% (€351 million) for pharmacological treatments, 3% (€71 million) for ambulatory visits, and 0.6% (€13 million) for social security costs. The average yearly cost per patient was equal to €8691 (€8591 for hospitalisations). Analysing severe patients, hospitalisation costs increase to €12,336 (+ 44% if compared to non-severe osteoporosis patients).
The analysis showed that osteoporosis represents one of the main health problems in Italy and the ability to maintain patients in a non-severe health state could decrease the economic burden from both NHS and social perspective.
如今,骨质疏松症是最常见的骨骼疾病,也是所有发达国家的一个重要公共卫生问题。本研究旨在评估与骨质疏松症管理和治疗相关的成本,以评估 2017 年意大利的直接医疗成本和社会保障成本的经济负担。
开发了一种疾病成本模型,以估算 NHS(国家卫生服务)和意大利社会保障系统每年承担的平均成本。进行了系统的文献综述,以获得可用的流行病学、直接和间接成本参数。考虑到 2008-2016 年住院记录的行政数据库,计算了住院费用。如果患者符合以下后续纳入标准,则将其纳入分析:年龄≥45 岁,在初级或次级诊断中存在骨质疏松症(ICD9-CM 733.0)和/或在以下部位存在主要骨折的初级或次级诊断(不包括道路事故):脊柱(ICD9-CM 代码:805;806)、股骨(ICD9-CM 代码:820;821)、桡骨和尺骨(ICD9-CM 代码:813.4;813.5)、肱骨(ICD9-CM 代码:812.0-812.5)、骨盆(ICD9-CM 代码:808)、胫骨和腓骨(ICD9-CM 代码:823)、踝部(ICD9 代码:824)和肋骨(ICD9-CM 代码:807.0;807.1)。考虑与每个住院相关的诊断相关组(DRG)国家关税来估计成本。最后,分析了意大利国家社会保障研究所(INPS)的行政数据库(2009-2015 年),以从社会角度估算养老金和残疾成本。
该模型估计意大利骨质疏松症的平均年度经济负担为 22 亿欧元。在该成本中,约 80%(18 亿欧元)与住院有关,16%(3.51 亿欧元)与药物治疗有关,3%(7100 万欧元)与门诊有关,0.6%(1300 万欧元)与社会保障成本有关。每位患者的平均年费用为 8691 欧元(住院费用为 8591 欧元)。分析严重患者,住院费用增加到 12336 欧元(与非严重骨质疏松症患者相比增加了 44%)。
分析表明,骨质疏松症是意大利的主要健康问题之一,能够使患者保持非严重健康状态可以降低 NHS 和社会的经济负担。